Giant Cell Arteritis Market Set to Experience Unprecedented Growth by 2034 - Estimates DelveInsight | Novartis, AbbVie, XOMA, Kiniksa, Eli Lilly, Janssen, Dr Reddys Laboratories, Roche, CSL, Johnson & Johnson, MorphoSys

DelveInsight's "Giant Cell Arteritis Market Insights, Epidemiology, and Market Forecast 2034" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Giant Cell Arteritis Market Size and Share in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The market report covers emerging drugs, treatment practices, market share of individual Giant Cell Arteritis therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current Giant Cell Arteritis treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.

Giant Cell Arteritis: An Overview
Giant Cell Arteritis (GCA), also called temporal arteritis, is a vasculitis that affects large and middle-sized blood vessels with a predisposition to the involvement of cranial arteries derived from the carotid artery in individuals older than 50 years of age. It is primarily a disease of cell-mediated immunity, which is thought to arise as a maladaptive response to endothelial injury. Actinic damage to the temporal artery from chronic sun exposure has been proposed as one source of the injury.

GCA is classified as a large-vessel vasculitis but also involves medium and small arteritis, particularly the superficial temporal arteritis- hence it is termed temporal arteritis. Along with this, GCA most commonly affects the ophthalmic, occipital, vertebral, posterior ciliary, and proximal vertebral arteries. Medium- and large-sized vessels may be involved, including the aorta and the carotid, subclavian, and iliac arteries.

Giant Cell Arteritis Market Key Facts
• In 2023, the total market size of Giant-Cell Arteritis was around USD 960 million, which is expected to increase by 2034.
• Among the 7MM, the United States accounted for the highest market size in 2023, followed by the United Kingdom for Giant-Cell Arteritis.
• During the forecast period (2024-2034), pipeline candidates such as COSENTYX, RINVOQ and TREMFYA are expected to drive the rise in Giant-Cell Arteritis market size.
• In 7MM, the United States accounted for the highest number of diagnosed prevalent cases of Giant-Cell Arteritis, which is 54.0% of the diagnosed prevalent cases of Giant-Cell Arteritis in 2023.
• Among the EU4 and the UK, the United Kingdom accounted for the highest number of Giant-Cell Arteritis cases, followed by France, whereas Spain accounted for the lowest number of Giant-Cell Arteritis cases.

Get a Detailed Overview of the Evolving Giant Cell Arteritis Market Trends @
https://www.delveinsight.com/report-store/giant-cell-arteritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Giant Cell Arteritis Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Giant Cell Arteritis therapies in the market. It also provides a detailed assessment of the Giant Cell Arteritis market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete details of the market trend for each marketed Giant Cell Arteritis drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Discover How the Giant Cell Arteritis Market Will Grow by 2034 @
https://www.delveinsight.com/report-store/giant-cell-arteritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Giant Cell Arteritis Epidemiology
The epidemiology section covers detailed insights into the historical, and current Giant Cell Arteritis patient pool and forecasted epidemiology trends for every seven major countries (7MM) from 2020 to 2034.

The Report Covers the Giant Cell Arteritis Epidemiology Segmented as -
• Total Age group-specific Cases of Giant Cell Arteritis
• Total Prevalent Cases of Giant Cell Arteritis
• Total Subtype-specific Cases of Giant Cell Arteritis
• Total Treated Cases of Giant Cell Arteritis
• Total Clinical Manifestation-specific Cases of Giant Cell Arteritis

Get Key Insights Into the Evolving Giant Cell Arteritis Epidemiology Trends @
https://www.delveinsight.com/report-store/giant-cell-arteritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Giant Cell Arteritis Drugs Uptake and Pipeline Development Activities
The drugs' uptake section focuses on the rate of uptake of the potential drugs recently launched in the Giant Cell Arteritis market or expected to be launched during the study period. The analysis covers the market share by Giant Cell Arteritis drugs, patient uptake by therapies, and sales of each drug.

The report's drugs uptake section helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It allows the comparison of the drugs based on market share and size, which again will be helpful in investigating factors important in understanding the market dynamics and in making financial and regulatory decisions.

The report also covers the Giant Cell Arteritis Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Explore More About Ongoing Pipeline Development Activities in the Giant Cell Arteritis Market @
https://www.delveinsight.com/sample-request/giant-cell-arteritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Giant Cell Arteritis Therapeutics Assessment
Currently, there is just one therapy that is approved in the 7MM for the treatment of giant cell arteritis, which includes Chugai Pharmaceuticals/Roche's Actemra/RoActemra (Tocilizumab). However, several major pharma and biotech companies are developing therapies for Giant-Cell Arteritis to improve the treatment scenario. Novartis is leading the therapeutics market with its Giant-Cell Arteritis drug candidates in the most advanced stage of clinical development.

Leading Companies in the Giant Cell Arteritis Therapeutics Market Include
Some of the key companies in the Giant Cell Arteritis Therapeutics Market include Novartis, AbbVie, XOMA, Kiniksa Pharmaceuticals, Eli Lilly and Company, Janssen Biotech, Dr Reddys Laboratories, Roche Holding, AbbVie, Novartis Pharmaceuticals, CSL, Johnson & Johnson, MorphoSys AG, and many others.

Emerging and Marketed Giant Cell Arteritis Therapies Covered in the Report Include
• Cosentyx (secukinumab): Novartis Pharmaceuticals
• KPL-301 (mavrilimumab): CSL/Kiniksa Pharmaceuticals
• Tremfya (guselkumab): Johnson & Johnson/MorphoSys AG
• Rinvoq (upadacitinib): AbbVie
• Actemra / RoActemra (Tocilizumab): Roche Holding
And Many More

Learn More About the Emerging Therapies and key Companies in the Giant Cell Arteritis Therapeutics Market @
https://www.delveinsight.com/sample-request/giant-cell-arteritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Giant Cell Arteritis Competitive Intelligence Analysis
4. Giant Cell Arteritis Market Overview at a Glance
5. Giant Cell Arteritis Background and Overview
6. Giant Cell Arteritis Patient Journey
7. Giant Cell Arteritis Epidemiology and Patient Population
8. Giant Cell Arteritis Treatment Algorithm, Current Treatment, and Medical Practices
9. Giant Cell Arteritis Unmet Needs
10. Key Endpoints of Giant Cell Arteritis Treatment
11. Giant Cell Arteritis Marketed Products
12. Giant Cell Arteritis Emerging Therapies
13. Giant Cell Arteritis Seven Major Market Analysis
14. Attribute Analysis
15. Giant Cell Arteritis Market Outlook (7 major markets)
16. Giant Cell Arteritis Access and Reimbursement Overview
17. KOL Views on the Giant Cell Arteritis Market.
18. Giant Cell Arteritis Market Drivers
19. Giant Cell Arteritis Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.

Download the Sample PDF to Get Detailed Insights About the Report's Offerings @
https://www.delveinsight.com/sample-request/giant-cell-arteritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager (Marketing & Branding)
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.